Eureka Therapeutics Appoints Surgical Oncologist Dr. Jennifer F. Tseng to Scientific Advisory Board

Emeryville, Calif., November 3, 2026 – Eureka Therapeutics, Inc., a clinical-stage biotechnology company pioneering safer and more effective T-cell therapies, today announced the appointment of Jennifer F. Tseng, MD, MPH, a nationally recognized surgical oncologist, to its Scientific Advisory Board. Dr. Tseng will advise Eureka on the clinical development of its ARTEMIS® CAR-T programs for solid tumors, with a focus on indication strategy and clinical trial design.

Dr. Tseng currently serves as the inaugural Executive Director, Chief Scientific Officer and a Trustee of the Ben and Rose Cole Charitable PRIA Foundation, a foundation dedicated to advancing pancreatic cancer care and research.

Dr. Tseng previously served as the James Utley Professor and Chair of Surgery at Boston University Chobanian & Avedisian School of Medicine and Surgeon-in-Chief at Boston Medical Center. Before that, she was Chief of Surgical Oncology at Beth Israel Deaconess Medical Center, where she became the first woman at BIDMC to reach the rank of Professor of Surgery at Harvard Medical School. She has built a research program focused on cancer surgery outcomes and is a past president of the Society for Surgery of the Alimentary Tract and the Society of Asian Academic Surgeons. She also served as a Director and Councilor of the American Board of Surgery.

“Eureka’s work on novel T-cell therapies has the potential to address a long-standing challenge in treating solid tumors,” said Dr. Tseng. “I look forward to joining the team and offering a clinical perspective to help advance new treatment options for patients worldwide.”

“Dr. Tseng brings extensive experience in cancer care and outcomes research,” said Cheng Liu, PhD, Founder and CEO of Eureka Therapeutics. “Her clinical insights will help guide the development of our ARTEMIS® T-cell therapies for solid tumors.”

ABOUT EUREKA THERAPEUTICS, INC.

Eureka Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Emeryville, California, developing novel T-cell therapies for solid tumors. Its proprietary ARTEMIS® CAR-T platform is designed to overcome key limitations of conventional CAR-T therapies by reducing toxicity, supporting higher doses and repeat infusions, improving T-cell persistence, and enhancing tumor infiltration, with the goal of achieving more durable anti-tumor responses. Eureka’s clinical-stage ARTEMIS® T-cell programs, GPC3-targeting ECT204 (ARYA-3) for adults and AFP-targeting ET140203 (ARYA-2) for pediatric patients, are in Phase I/II clinical trials for advanced liver cancer. In collaboration with the National

Cancer Institute (NCI), Eureka is also developing ARTEMIS® T-cell therapies targeting mesothelin (MSLN) for pancreatic cancer and other MSLN-expressing solid tumors and GPC2 for neuroblastoma. For more information, please visit http://www.eurekatherapeutics.com.

CONTACTS:

Eureka Therapeutics, Inc.
Investor Relations
510-318-9215
IR@eurekainc.com

Share:
Facebook
Twitter
LinkedIn

Alexa Willson

CFO

Alexa Willson has served as the Chief Financial Officer of Eureka Therapeutics since August 2022. Prior to joining the company, She was a Managing Partner of Cloudstone Venture Capital, an early-stage healthtech venture firm since October 2020. Cloudstone is also an investor of Eureka Therapeutics.

Ms. Willson has over 25 years of experience advising public and private companies on corporate finance, strategy, capital raising, valuation, mergers & acquisitions, and other matters. She has founded and run a midmarket investment banking boutique and worked with large Wall Street investment banks, including Kidder Peabody and Drexel Burnham.

Ms. Willson has served on private and non-profit boards and investment committees in various capacities. She teaches financial literacy. Ms. Willson holds a BA from Harvard and an MBA from Stanford Graduate School of Business.